# Human Gene Therapy for Hemophilia:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/human-gene-therapy-for-hemophilia-guidance-for-industry/bceafce9-c9f0-4137-9ca5-071464212a06

> FDA guidance document: Human Gene Therapy for Hemophilia:  Guidance for Industry. Issue date: January 28, 2020. Get complete insights and analysis.

---

## Details

- Title: Human Gene Therapy for Hemophilia:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Biologics Evaluation and Research
- Office URL: /offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d
- Issue Date: 2020-01-28
- Comment Close Date: 2018-10-18
- Last Changed: 2025-01-31
- Docket Number: <a href="https://www.regulations.gov/docket/FDA 2018-D-2238">FDA 2018-D-2238</a>

## Related Documents

- [Human Gene Therapy for Rare Diseases:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/human-gene-therapy-for-rare-diseases-guidance-for-industry/1cebc8e2-7d3b-4c5f-a4c4-78d1fc112099)
- [Human Gene Therapy for Retinal Disorders:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/human-gene-therapy-for-retinal-disorders-guidance-for-industry/3bca1550-9cef-41e0-b826-9a48c8984afa)
- [Long Term Follow-up After Administration of Human Gene Therapy Products:   Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/long-term-follow-up-after-administration-of-human-gene-therapy-products-guidance-for-industry/5f3e0db9-8c8a-45b5-864f-6250a3250b1b)